Evaluation of potent antiviral therapy in patients with chronic hepatitis B. Entry In the treatment of chronic hepatitis B (CHB) targeted; life expectancy of patients prolongation and long-term illness especially the complications Hepatocellular Carcinoma (HSC) is protection. Among other targets prevention of mother-to-child transmission, HBV reactivation and HBV-related extrahepatic events are prevented. The most in treatment important endpoint is HBV DNA suppression. providing and long-term 1 probability of reaching these goals. The time of initiation of treatment is important. This the stage of the disease to determine the time and patient age is taken into account. in the advanced HBV first target in patients with cirrhosis suppression of the second target is the development of HCC. is to prevent. Final choice of treatment one of the guides 2019 European Association for the Study of the Liver (EASL), strong and resistance barrier as the first choice Entecavir (ETV), Tenofovir disoproxil (TDF) or Tenofovir alafenamide long-term application of (TAF) treatments 2 ETV since 2006, TDF in our country since 2008. are potent antivirals. In this study, in our outpatient with regular follow-up, good drug compliance In patients who started ETV or TDF treatment, virological, serological and biochemically long term evaluation of its effectiveness intended. Method Study A retrospective clinical The study was conducted between 2007 and 2015. Infection in a tertiary hospital Diseases and Clinical Microbiology was done in the clinic. Erciyes for work From the Ethics Committee of the University of Medicine (No. 96681246) has been approved. In the study, those diagnosed with CHB, 111 who had not received prior oral antiviral therapy patients were included (54 in the TDF group, ETV 57 in the group). Inclusion criteria for the study; 18 age and above, under 70 years of age, for longer than six months HBsAg positivity at the beginning of treatment HBV DNA 104 copies/ml, liver Histology Ishak stage two and above histology with an activity index (HAI) of below or above, TDF or ETV for more than a month used patients were included. of patients After starting ETV/TDF therapy follow-up times were recorded. Exclusion Criteria in the Study; Autoimmunity, metabolic liver disease, decompensated cirrhotic patients, pregnancy, chronic kidney failure, heart failure and COPD Patients with such conditions were excluded. Treatment response in patients in its evaluation; For viral suppression HBV DNA negative, biochemical In response, ALT reduction was also checked. In addition, changes in hepatitis serologies was also recorded. HBV DNA levels “Cobas TaqManTM 48” (Roche Laboratories, Germany) was measured with the Real-Time PCR system. HBV DNA negative value <100 copies/ml was accepted as ALT level biochemical determined by the method. The lower limit is 40 IU/L determined. As a serological indicator, HBsAg, antiHBs, HBeAg, antiHBe positive/negative changes are saved. in laboratory follow-up ratings 6. 12, 24, 36, 48, 60 and 72. was done at monthly follow-ups. Oral antiviral drug changes was recorded. Patients undergoing medication changes not working after change removed. Before starting treatment, patients liver biopsy materials Ishak score 4 Patients' baseline Histological Activity Index (HAI) and fibrosis (stage) scores were recorded. The diagnosis of cirrhotic patients is clinical, biochemical (Transaminases, albumin level, PT, hypersplenism) and histological According to the stage (Ishak stage 4 and above) determined. Statistical analysis SPSS for data evaluation statistical package program for windows 20.0 used. Regarding the measurable variable data mean ± standard deviation and percentage presented with. Categorical data Chi-square test was used for comparison. Comparison of non-categorical data Mann Whitney U test was used for p<0.05 values ​​that are statistically significant accepted. Results The patients included in the study demographic characteristics are listed in Table 1. Accordingly, age, gender, IFN use history, ALT level, histology statistical difference between evaluations not seen. Initial HBV DNA of patients level (p=0.02), HBeAg positivity rate TDF group (p=0.05), treatment follow-up was higher. duration was higher in the ETV group. (p=0.04). 99 of the patients included in the study (89%) liver biopsy was performed and 12 (11%) hemangioma and coagulation biopsy for reasons such as determined that it could not be done. Virological response Patients in both groups HBV DNA levels during follow-up Table It was shown in 2. Initial HBV DNA value Although higher in the TDF group, HBV DNA suppression at 6 and 12 months In ETV group compared to TDF group statistically significantly more found to be excessive (p=0.001; p=0.03).